

Amendment
U.S. Patent Application No. 10/088,750

REMARKS

Applicants have amended the specification to further clarify the sequence ID numbers from the Sequence Listing filed herewith. The Amendment does not introduce new matter, and is supported by the application.


Continued examination of the present application is respectfully requested.

CONCLUSION

Applicants respectfully request consideration of this application and timely allowance of the pending claims. Should the Examiner deem that any further action by Applicants or Applicants' undersigned representative is desirable and/or necessary, the Examiner is invited to telephone the undersigned at the number set forth below.

If there are any other fees due in connection with the filing of this response, please charge the fees to deposit Account No. 50-0925. If a fee is required for an extension of time under 37 C.F.R. § 1.136 not accounted for above, such extension is requested and should also be charged to said Deposit Account.

Respectfully submitted,


Luke A. Kilyk
Reg. No. 33,251

Atty. Docket No. 3190-015
KILYK & BOWERSOX, P.L.L.C.
53 A East Lee Street
Warrenton, VA 20186
Tel: (540) 428-1701
Fax.: (540) 428-1720

VERSION WITH MARKINGS TO SHOW CHANGES MADE

IN THE SPECIFICATION:

On page 15, paragraph beginning on line 23 and ending on line 19 of page 16.

The amplification of the mutant fragments was carried out using synthesized DNA primers containing mutation sequences and a high fidelity DNA polymerase (KOD Dash, Toyobo Co., Japan), and the amplified fragments were purified by the agarose electrophoresis, phosphorylated, self-ligated, and transformed in *Escherichia coli*. Substitution of the nucleotide was confirmed by DNA-sequencing. Deletion and substitution of the spiral part of stem loop III was carried out by the fusion PCR (Virology 214, 611-618 (1995)). A forward primer (GGTTAAATTTTCGAGGTAAAAAATTGCTATA), SEQ ID NO. 8, containing nt6029-6050 and nt6062-6080 of PSIV sequence and a reverse primer containing nt27-5 of pT7Blue (Novagen, Inc.) were synthesized for the initial amplification to delete nucleotide (nt) 6051-6061. Then, a reverse primer (CCTCGAAATTTAACCAGATCACATAGTCAGCTTTC), SEQ. ID. NO. 9, containing nt6043-6029 and nt6017-5998 of PSIV sequence and a forward primer containing nt28-47 of pT7Blue (Novagen, Inc.) were synthesized for another initial amplification to delete nt6028-6018. Underlines of these primers indicate 15nt overlap of the fusion PCR. After each initial amplification using these two primer sets, two amplified DNA fragments were mixed and fused according to the description in Ref. 17. The final amplification was carried out using primers carrying nt28-47 and nt27-5 of pT7Blue, and the amplified DNA fragments were purified with a gel, phosphorylated, and ligated. The initial amplification was carried out using longer primers containing a substituted nucleotide to substitute the helical part.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): NAKASHIMA et al.

Application No.: 10/088,750

Filed: March 20, 2002

Title: A NOVEL HIGHER-ORDER STRUCTURE WITH
PROMOTING TRANSLATION ACTIVITY

Attorney Docket No.: 3190-015

Group Art Unit: To Be Assigned

Examiner: To Be Assigned

Commissioner for Patents
Washington, D.C. 20231

DRAWING TRANSMITTAL LETTER

Sir:

Enclosed herewith please find:

- (X) 2 sheets of redlined drawing(s) which indicate proposed changes to the drawing(s). Upon approval of these proposed changes, formal drawing(s) will be submitted.
- () _____ sheets of corrected formal drawing(s), as required by the Notice of Patent Drawings Objection (PTO-948) which accompanied the Office Action dated _____.
- () _____ sheets of corrected formal drawing(s), as required by the Notice of Patent Drawing(s) Objection (PTO-948) and approved in the Notice of Allowability dated _____.
- () _____ sheets of formal drawing(s). Please substitute these formal drawing(s) for the informal drawing(s) originally filed.

Examiner's approval of the entry of these drawings is respectfully requested. No new matter has been added.

Respectfully Submitted,

'Express Mail' label no. EV152266267 US

Date of Deposit: July 18, 2002

I hereby certify that this is being deposited with the United States Postal Service 'Express Mail Post Office to Addressee' service under 37 CFR 1.10 on the date indicated above and is addressed to the Commissioner for Patents, Washington, D.C. 20231.

Typed Name: Dawn M. Berry

Signature: Dawn M. Berry

By Luke A. Kilyk

Luke A. Kilyk

Reg. No. 33,251

KILYK & BOWERSOX, P.L.L.C.

53 A East Lee Street


Warrenton, VA 20186

Date: July 18, 2002

Tel. (540) 428-1701

Fax: (540) 428-1720

SEQ ID No. 10



BEST AVAILABLE COPY

